Joclab Injection contains Cladribine at a concentration of 1 mg/ml, a purine nucleoside analog used primarily in the treatment of certain hematological malignancies. Cladribine exerts its therapeutic effect by interfering with DNA synthesis, leading to the inhibition of lymphocyte proliferation and induction of apoptosis in malignant cells. This mechanism makes it particularly effective in the management of hairy cell leukemia, chronic lymphocytic leukemia, and other lymphoproliferative disorders. Joclab Injection is administered intravenously under strict medical supervision, with dosing regimens tailored according to the specific indication and patient response. The drug’s pharmacokinetics include rapid cellular uptake and prolonged intracellular retention, contributing to its sustained cytotoxic activity. Common adverse effects may include myelosuppression, immunosuppression, fever, and infusion-related reactions, necessitating regular monitoring of blood counts and patient status throughout therapy. Due to its immunosuppressive properties, patients should be evaluated for active infections prior to initiation, and appropriate prophylactic measures should be considered. Joclab Injection is contraindicated in patients with hypersensitivity to Cladribine or its components. Careful assessment of renal and hepatic function is recommended before and during treatment to minimize toxicity. This agent should be used with caution in pregnant or breastfeeding women.